February 21, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the world’s first 

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart disease patient—and the first ever in Michigan—to receive a new transcatheter heart valve device for treating severe tricuspid regurgitation. She is only the third patient in the U.S. to receive the device.

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an academic institution, Hackensack Meridian Jersey Shore University Medical Center provides patients with state-of-the-art clinical trials in the management of heart valve disease and 

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or no treatment options, announced a collaboration with Population Health Research Institute (PHRI), a joint institute of McMaster University and Hamilton Health Sciences in Canada, to advance a clinical pr

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, have announced that the first patient has been randomized in the GenePHIT (Gene PHosphatase Inhibition Therapy) trial